Citations

Showing 10 of 108104 citations.

A Comparison of Perceived Lifetime Breast Cancer Risk to Calculated Lifetime Risk Using the Gail Risk Assessment Tool
Mehta, Jaya , MacLaughlin, Kathy L. , Millstine, Denise , Wallace, Mark R. , Fields, Heather , Ruddy, Barbara E., Bryan, Michael , Golafshar, Michael A. , Millstine, Denise M, Shah, Amit A, Fields, Heather E, Bryan, Michael J, Kling, Juliana M , Golafshar, Michael , Faubion, Stephanie S. , Shah, Amit , Patel, Bhavika , Buras, Matthew , Kling, Juliana M.

Mayo Clinic

Journal of Women's Health | January 18, 2022 | Volume: 31 | Issue: 3 | Pages: 356-361

10.1089/jwh.2019.8231 | PMID 35041492 Get It

Background: Understanding the accuracy of a woman's perceived breast cancer risk can enhance shared decision-making about breast cancer screening through provider and patient discussion. We aim to report and compare women's perceived lifetime breast cancer risk to calculated lifetime breast cancer risk. Methods: Women presenting to Mayo Clinic in Arizona and Minnesota in July 2016 completed a survey assessing their perceived breast cancer risk. Lifetime Gail risk scores were calculated from questions pertaining to health history and were then compared with perceived breast cancer risk. Results: A total of 550 predominantly white, married, and well-educated (≥college) women completed surveys. Using lifetime Gail risk scores, 5.6% were classified as high risk (>20% lifetime risk), 7.7% were classified as intermediate risk (15%–20%), and 86.6% were classified as average risk (<15%). Of the 27 women who were classified as high risk, 18 (66.7%) underestimated their risk and of the 37 women who were intermediate risk, 12 (32.4%) underestimated risk. Women more likely to underestimate their risk had a reported history of an abnormal mammogram and at least one or more relative with a history of breast cancer. Surveyed women tended to overestimate risk 4.3 (130/30) times as often as they underestimated risk. Conclusion: In a group of predominantly white, educated, and married cohort of women, there was a large portion of women in the elevated risk groups who underestimated risk. Specific aspects of medical history were associated with underestimation including a history of abnormal mammogram and family history of breast cancer. Overall, in our sample, more women overestimated than underestimated risk.
Transpharyngeal Approaches for Management of Oropharyngeal Squamous Cell Carcinoma: Mayo Clinic Institution Experience
Badaoui, Joseph N. , Sauer, Adam , Moore, Eric J. , Lohse, Christine M. , Kasperbauer, Jan L. , Noel, Daniel B., Olsen, Kerry D., Abel, Kathryn M. Van , Sauer, Adam B, Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 18, 2022 | Volume: 167 | Issue: 3 | Pages: 509-516

10.1177/01945998211071000 | PMID 35041566 Get It

ObjectiveInvestigate oncologic and functional outcomes associated with transhyoid and lateral pharyngotomy (transpharyngeal) approaches in the treatment of oropharyngeal squamous cell carcinoma (OPSCC).Study DesignRetrospective review.SettingSingle institution (tertiary care center).MethodsThis is a retrospective case series of patients with OPSCC undergoing transpharyngeal resection from 1990 to 2017 at Mayo Clinic. Oncologic outcomes, postoperative complications, objective swallowing data, and rates of tracheostomy and percutaneous gastrostomy tube dependence were recorded.ResultsOf 83 patients meeting inclusion criteria, 56 (68%) were human papillomavirus positive. Overall survival rates at 5 and 10 years following surgery were 85% and 80%, respectively. Cancer‐specific survival rates at these same time points were 90% and 88%. Following treatment, 35 of 49 patients (71%) had a Functional Oral Intake Scale score ≥5, indicating total oral intake of multiple consistencies; 79 of 82 (96%) were without tracheostomy or laryngectomy; and 71 of 81 (88%) were on a full oral diet.ConclusionTranspharyngeal approaches provide adequate functional and oncologic outcomes in the majority of patients with OPSCC. These results may have important implications for patients who are not candidates for, or are unwilling to undergo, nonoperative therapy or for those without access to radiation therapy.
Catchment Profile of Large Cochlear Implant Centers in the United States
Nassiri, Ashley M. , Holcomb, Meredith A. , Perkins, Elizabeth L. , Bucker, Andrea L., Prentiss, Sandra , Welch, Christopher M. , Andresen, Nick S., Valenzuela, Carla V. , Wick, Cameron C. , Angeli, Simón I., Sun, Daniel Q. , Bowditch, Stephen P., Brown, Kevin D. , Zwolan, Teresa A. , Haynes, David S. , Saoji, Aniket A. , Carlson, Matthew L. , Perkins, Elizabeth L

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 18, 2022 | Volume: 167 | Issue: 3 | Pages: 545-551

10.1177/01945998211070993 | PMID 35041546 Get It

ObjectiveTo characterize the catchment area and patient profile of large cochlear implant (CI) centers in the United States.Study DesignMulti‐institutional retrospective case series.SettingTertiary referral CI centers.MethodsPatients who underwent CI surgery at 7 participating CI centers between 2015 and 2020 were identified. Patients’ residential zip codes were used to approximate travel distances and urban vs rural residential areas.ResultsOver the 6‐year study period (2015‐2020), 6313 unique CI surgical procedures occurred (4529 adult, 1784 pediatric). Between 2015 and 2019, CI procedures increased by 43%. Patients traveled a median 52 miles (interquartile range, 21‐110) each way; patients treated at rural CI centers traveled greater distances vs those treated at urban centers (72 vs 46 miles, P <. 001). Rural residents represented 61% of the patient population and traveled farther than urban residents (73 vs 24 miles, P <. 001). Overall, 91% of patients lived within a 200‐mile radius of the institution, while 71% lived within a 100‐mile radius. In adults, multiple regression analysis redemonstrated an association between greater travel distances and (1) older age at the time of CI and (2) residential rural setting (both P <. 001, r2 = 0.2).ConclusionsWhile large CI centers serve geographically dispersed populations, most patients reside within a 200‐mile radius. Strategies to expand CI utilization may leverage remote programming, telemedicine, and strategic placement of new centers and satellite clinics to ameliorate travel burden.
Comprehensive assessment of multimorbidity burden in a population-based cohort of patients with rheumatoid arthritis
Crowson, Cynthia S. , Gunderson, Tina M. , Dykhoff, Hayley J. , Myasoedova, Elena , Atkinson, Elizabeth J. , Kronzer, Vanessa L. , Coffey, Caitrín M. , Davis Iii, John M, Kronzer, Vanessa L , Myasoedova, Elena , Davis, John M.

Mayo Clinic

RMD Open | January 18, 2022 | Volume: 8 | Issue: 1 | Pages: e002022

10.1136/rmdopen-2021-002022 | PMID 35042730 Get It

Objective To comprehensively assess multimorbidity burden in patients with rheumatoid arthritis (RA) in order to unify the multimorbidity definition for RA research and clinical practice. Methods In this population-based study, residents of eight Minnesota counties with prevalent RA on 1 January 2015 were identified. Age, sex and county-matched non-RA comparators were selected from the same population. Diagnostic codes were retrieved for 5 years before 1 January 2015. Using two codes ≥30 days apart, 44 previously defined morbidities and 78 non-overlapping chronic disease categories based on Clinical Classification Software were defined. Prevalence of each morbidity in the RA versus non-RA cohorts was compared using false discovery rate to adjust for multiple comparisons. Morbidities more common in RA than non-RA and those with prevalence ≥5% were retained. Results 1643 patients with RA and 1643 non-RA subjects (72% women; mean age 63.1 years) were studied. Using the 44 morbidities, multimorbidity (defined as 2+ morbidities) was present in 1411 (86%) of RA and 1164 (71%) of non-RA subjects (p<0.001) with 5+ morbidities present in 907 (55%) of RA and 619 (38%) of non-RA (p<0.001). Patients with RA had significantly higher prevalence of 24 of the 44 morbidities compared with non-RA, especially interstitial lung disease, fibromyalgia, osteoarthritis and osteoporosis. Among the additional 78 categories, 7 were significantly higher in RA than non-RA, including organic sleep disorders, vitamin D deficiency and foot ulcers. Conclusion Patients with RA have a higher prevalence of multimorbidity compared with non-RA subjects. These results confirm the list of 44 morbidities and add several other morbidities of interest in RA.
Lipid kinases VPS34 and PIKfyve coordinate a phosphoinositide cascade to regulate retriever-mediated recycling on endosomes
Giridharan, Sai Srinivas Panapakkam , Luo, Guangming , Rivero-Ríos, Pilar , Steinfeld, Noah , Tronchère, Hélène , Singla, Amika , Billadeau, Daniel D. , Sutton, Michael A. , Burstein, Ezra , Sutton, Michael A , Weisman, Lois S , Burstein, Ezra

Mayo Clinic

eLife | January 18, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.69709 | PMID 35040777 Get It

Cell surface receptors control how cells respond to their environment. Many cell surface receptors recycle from endosomes to the plasma membrane via a recently discovered pathway, which includes sorting-nexin SNX17, Retriever, WASH, and CCC complexes. Here, using mammalian cells, we discover that PIKfyve and its upstream PI3-kinase VPS34 positively regulate this pathway. VPS34 produces phosphatidylinositol 3-phosphate (PI3P), which is the substrate for PIKfyve to generate PI3,5P 2 . We show that PIKfyve controls recycling of cargoes including integrins, receptors that control cell migration. Furthermore, endogenous PIKfyve colocalizes with SNX17, Retriever, WASH, and CCC complexes on endosomes. Importantly, PIKfyve inhibition results in displacement of Retriever and CCC from endosomes. In addition, we show that recruitment of SNX17 is an early step and requires VPS34. These discoveries suggest that VPS34 and PIKfyve coordinate an ordered pathway to regulate recycling from endosomes and suggest how PIKfyve functions in cell migration.
The influence of the blood–brain barrier in the treatment of brain tumours
Rathi, Sneha , Griffith, Jessica I. , Zhang, Wenjuan , Zhang, Wenqiu , Oh, Ju‐Hee , Elmquist, William F. , Zhang, Wenqiu , Zhang, Wenjuan , Zhang, Wenqiu , Talele, Surabhi , Sarkaria, Jann N.

Mayo Clinic

Journal of Internal Medicine | January 18, 2022 | Volume: 292 | Issue: 1 | Pages: 3-30

10.1111/joim.13440 | PMID 35040235 Get It

AbstractBrain tumours have a poor prognosis and lack effective treatments. The blood–brain barrier (BBB) represents a major hurdle to drug delivery to brain tumours. In some locations in the tumour, the BBB may be disrupted to form the blood–brain tumour barrier (BBTB). This leaky BBTB enables diagnosis of brain tumours by contrast enhanced magnetic resonance imaging; however, this disruption is heterogeneous throughout the tumour. Thus, relying on the disrupted BBTB for achieving effective drug concentrations in brain tumours has met with little clinical success. Because of this, it would be beneficial to design drugs and drug delivery strategies to overcome the ‘normal’ BBB to effectively treat the brain tumours. In this review, we discuss the role of BBB/BBTB in brain tumour diagnosis and treatment highlighting the heterogeneity of the BBTB. We also discuss various strategies to improve drug delivery across the BBB/BBTB to treat both primary and metastatic brain tumours. Recognizing that the BBB represents a critical determinant of drug efficacy in central nervous system tumours will allow a more rapid translation from basic science to clinical application. A more complete understanding of the factors, such as BBB–limited drug delivery, that have hindered progress in treating both primary and metastatic brain tumours, is necessary to develop more effective therapies.
Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2‐negative individuals who had genetic testing in a large urban comprehensive cancer center
Tatineni, Sushma , Tarockoff, Meri, Abdallah, Nadine , Purrington, Kristen S. , Assad, Hadeel , Reagle, Rachel, Petrucelli, Nancie , Simon, Michael S. , Purrington, Kristen S

Mayo Clinic

Cancer Medicine | January 18, 2022 | Volume: 11 | Issue: 6 | Pages: 1465-1473

10.1002/cam4.4541 | PMID 35040284 Get It

AbstractBackgroundThere is sparse clinical information on the racial and ethnic distribution of results of multigene panel testing among individuals at high risk for hereditary cancer.MethodsWe evaluated the results of multigene panel testing across eight clinical sites across the state of Michigan for individuals seen for genetic counseling from May 13, 2013 to October 31, 2019 at the Karmanos Cancer Institute's cancer genetics clinic. We estimated the prevalence of pathogenic variants and variants of uncertain significance (VUS) from genes other than BRCA1/2 among individuals of non‐Hispanic White (NHW), Black or African American (AA), Ashkenazi Jewish (AJ), Arab, Hispanic, and other ancestry.ResultsThe racial and ethnic distribution of 2419 individuals who had panel testing included 68.8% NHW, 22.1% AA, 2.3% Arab, 2.2% AJ, 1.0% Hispanic, and 3.6% other. Of these, 11.2% had pathogenic variants and 17.5% had VUS. After multivariable analyses, compared to NHW, AA were less likely to have pathogenic variants (OR 95% CI, 0.38, 0.24–0.59, p < 0.001). Both AA and Arabs were more likely to have VUS (OR 95% CI, 1.53, 1.18–1.98, p = 0.001 and OR 95% CI, 2.28, 1.17–4.43, p = 0.015, respectively). There were no significant differences for other groups. The most common pathogenic variants were CHEK2 (n = 65), MUTYH (n = 45), ATM (n = 28), and MSH2 (n = 22); the most common pathogenic variants by race and ethnicity were CHEK2 (NHW), MSH2 and MUTYH (AA), MSH2 (Arab), MSH6 and CHEK2 (AJ), and MLH1 (Hispanic); the most common pathogenic variants by primary cancer site were CHEK2 (breast), MSH2 (colon), BRIP1 and MUTYH (ovarian), and MSH2 and MSH6 (endometrial).ConclusionsUnderstanding the racial and ethnic distribution of pathogenic variants in multi‐gene panels has the potential to lead to better identification of individuals at risk for hereditary cancer.
Optimizing the nutrition support care model: Analysis of survey data
Mundi, Manpreet S. , Mechanick, Jeffrey I. , Patel, Jayshil J. , Bonnes, Sara L. , Blackmer, Allison B. , Christian, Vikram J. , Hennessy, Sara A. , Jain, Ajay K. , Kaspar, M., Katz, Jennifer , Labossiere, Reginald, Limketkai, Berkeley N. , Morrison, Chet A. , Newberry, Carolyn , Mohamed Elfadil, Osman , Patel, Jayshil J , Christian, Vikram J , Hurt, Ryan T. , Jain, Ajay , Limketkai, Berkeley N , Morrison, Chet A , Pimiento, Jose M , Rosenthal, Martin , Taylor, Beth , McClave, Stephen A , Mechanick, Jeffrey I. , Mundi, Manpreet S , Elfadil, Osman Mohamed , Kaspar, Matthew B., Katz, Jennifer, McCarthy, Paul Joseph , Pimiento, José M. , Rosenthal, Martin D. , Taylor, Beth , McClave, Stephen A.

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | January 18, 2022 | Volume: 46 | Issue: 7 | Pages: 1709-1724

10.1002/jpen.2326 | PMID 35040154 Get It

AbstractBackgroundMalnutrition is underrecognized and underdiagnosed, despite high prevalence rates and associated poor clinical outcomes. The involvement of clinical nutrition experts, especially physicians, in the care of high‐risk patients with malnutrition remains low despite evidence demonstrating lower complication rates with nutrition support team (NST) management. To facilitate solutions, a survey was designed to elucidate the nature of NSTs and physician involvement and identify needs for novel nutrition support care models.MethodsThis survey assessed demographics of NSTs, factors contributing to the success of NSTs, elements of nutrition education, and other barriers to professional growth.ResultsOf 255 respondents, 235 complete surveys were analyzed. The geographic distribution of respondents correlated with population concentrations of the United States (r = 90.8%, p < .0001). Most responding physicians (46/57; 80.7%) reported being a member of NSTs, compared with 56.5% (88/156) of dietitians. Of those not practicing in NSTs (N = 81/235, 34.4%), 12.3% (10/81) reported an NST was previously present at their institution but had been disbanded. Regarding NSTs, financial concerns were common (115/235; 48.9%), followed by leadership (72/235; 30.6%), and healthcare professional (HCP) interest (55/235; 23.4%). A majority (173/235; 73.6%) of all respondents wanted additional training in nutrition but reported insufficient protected time, ability to travel, or support from administrators or other HCPs.ConclusionCore actions resulting from this survey focused on formalizing physician roles, increasing interdisciplinary nutrition support expertise, utilizing cost‐effective screening for malnutrition, and implementing intervention protocols. Additional actions included increasing funding for clinical practice, education, and research, all within an expanded portfolio of pragmatic nutrition support care models.
Hepatology Highlights
Watkins, Ryan , Ilyas, Sumera I. , Penrice, Daniel D. , Conboy, Caitlin B. , Ayares, Gustavo , Arab, Juan Pablo

Mayo Clinic

Hepatology | January 17, 2022 | Volume: 75 | Issue: 2 | Pages: 241-242

10.1002/hep.32295 Get It

Current status and trends in subspecialty certification in physical medicine and rehabilitation
Sabharwal, Sunil , Kinney, Carolyn L. , Raddatz, Mikaela M. , Driscoll, Sherilyn W. , Francisco, Gerard E. , Robinson, Lawrence R. , Geis, Carolyn, Micheo, William , Robinson, Lawrence R , Kinney, Carolyn

Mayo Clinic

PM&R | January 17, 2022 | Volume: 15 | Issue: 2 | Pages: 212-221

10.1002/pmrj.12763 | PMID 35038251 Get It

AbstractBackgroundThere is a need to better understand the overall state of sub‐specialization in physical medicine and rehabilitation (PM&R).ObjectiveTo examine the status and trends in subspecialty certification for each of the seven subspecialties approved for American Board of Physical Medicine and Rehabilitation (ABPMR) diplomates.Design/SettingRetrospective analysis of deidentified information from the ABPMR database.ParticipantsPhysicians certified by ABPMR through 2019.InterventionsNot applicable.Main Outcome MeasuresFor each subspecialty, we examined: (1) the number of certificates issued to ABPMR diplomates; (2) the recertification rate; (3) the yearly trends for total active, new, and expired certificates; and (4) for ABPMR‐administered subspecialties, recertification rates for those entering the subspecialty through fellowship completion versus a “grandfathered” practice pathway.ResultsOf 11,421 ABPMR diplomates in the United States in 2019, a total of 3560 (31.2%) had 3985 active subspecialty certificates. Pain Medicine (PM) was the most common subspecialty certification (15.5% of all ABPMR diplomates) followed by Sports Medicine (SM, 6.6%), Brain Injury Medicine (BIM, 4.8%), Spinal Cord Injury Medicine (SCIM, 4.2%), Pediatric Rehabilitation Medicine (PRM, 2.5%), Neuromuscular Medicine (NMM, 0.7%), and Hospice and Palliative Medicine (HPM, 0.5%). For diplomates with more than one subspecialty certification, PM and SM was the most frequent combination. Both the recertification rate and the end of practice track eligibility influenced certification trends differently for individual subspecialties. The average number of new certificates added annually for every subspecialty was higher before than after the temporary practice track‐based eligibility ended; the difference was statistically significant (p < .05) for SCIM, PM, SM, and NMM. The recertification rate for all subspecialties combined was 73.4%. For the subspecialties (SCIM, PRM) for which these data were available, fellowship candidates had higher recertification rates than those grandfathered through a practice track.ConclusionThis report informs stakeholders about the state and evolution of subspecialty certification in PM&R over time.